In contrast, the prevalence of nonalcoholic fatty liver disease (NAFLD/NASH) increased from 1.2% (2013-2016) to 8.1% (2017-2022) (<i>p</i> < 0.001); anti-HBc (total) from 3.2% (2013-2016) to 5.1% (2017-2022) (<i>p</i> = 0.001), and autoimmune hepatitis (AIH) from 0.2% (2013-2016) to 0.4% (2017-2022) (<i>p</i> = 0.038) also showed a significant increase. This evidence concerns the gene KRT88P and metabolic dysfunction-associated steatotic liver disease.